患者男,67岁,进食后觉中上腹部不适10 d人院.无恶心、呕吐,无腹泻,腹部MRI疑胰头癌腹主动脉旁淋巴结转移及肝肾多发囊肿(图1a).否认肝炎、结核及糖尿病等病史.体格检查:体温36.7℃,呼吸18次/min,脉搏78次/min,血压121/68 mm Hg(1 mm Hg=...患者男,67岁,进食后觉中上腹部不适10 d人院.无恶心、呕吐,无腹泻,腹部MRI疑胰头癌腹主动脉旁淋巴结转移及肝肾多发囊肿(图1a).否认肝炎、结核及糖尿病等病史.体格检查:体温36.7℃,呼吸18次/min,脉搏78次/min,血压121/68 mm Hg(1 mm Hg=0.133 kPa),精神面容,营养中等.展开更多
OBJECTIVE To evaluate the feasibility of ^18F-deoxyglucose positron emission tomography (^18F-FDG PET) in the staging of non-small cell lung cancer(NSCLC). METHODS 105 patients with NSCLC had been examined by ^18F-FDG...OBJECTIVE To evaluate the feasibility of ^18F-deoxyglucose positron emission tomography (^18F-FDG PET) in the staging of non-small cell lung cancer(NSCLC). METHODS 105 patients with NSCLC had been examined by ^18F-FDG PET before radiotherapy. The results of the ^18F-FDG PET examination were compared with those of CT.RESULTS The staging was changed in 38 patients because of ^18F-FDG PET findings, with PET resulting in upstaging in 31 patients and downstaging in seven patients. Because of distant metastasis detected by PET, 21 patients received palliative treatment. Six of the seven downstaged patients underwent radical surgery, among which the PET findings were concordant with the pathological findings in five patients. Distant metastasis detected by PET elevated the pre-PET stage: at stage 110.0% (2/20), stage Ⅱ 14.3% (3/21) and stage Ⅲ 25.0% (16/64), respectively.CONCLUSION ^18F-FDG PET, by changing clinical staging in 36.2% (38/105) of NSCLC patients, has an impact on treatment strategy in NSCLC patients.展开更多
文摘患者男,67岁,进食后觉中上腹部不适10 d人院.无恶心、呕吐,无腹泻,腹部MRI疑胰头癌腹主动脉旁淋巴结转移及肝肾多发囊肿(图1a).否认肝炎、结核及糖尿病等病史.体格检查:体温36.7℃,呼吸18次/min,脉搏78次/min,血压121/68 mm Hg(1 mm Hg=0.133 kPa),精神面容,营养中等.
文摘OBJECTIVE To evaluate the feasibility of ^18F-deoxyglucose positron emission tomography (^18F-FDG PET) in the staging of non-small cell lung cancer(NSCLC). METHODS 105 patients with NSCLC had been examined by ^18F-FDG PET before radiotherapy. The results of the ^18F-FDG PET examination were compared with those of CT.RESULTS The staging was changed in 38 patients because of ^18F-FDG PET findings, with PET resulting in upstaging in 31 patients and downstaging in seven patients. Because of distant metastasis detected by PET, 21 patients received palliative treatment. Six of the seven downstaged patients underwent radical surgery, among which the PET findings were concordant with the pathological findings in five patients. Distant metastasis detected by PET elevated the pre-PET stage: at stage 110.0% (2/20), stage Ⅱ 14.3% (3/21) and stage Ⅲ 25.0% (16/64), respectively.CONCLUSION ^18F-FDG PET, by changing clinical staging in 36.2% (38/105) of NSCLC patients, has an impact on treatment strategy in NSCLC patients.
